The ECG is an investigation described over 100 years ago. It has stood the test of time and is still the first test used to identify acute myocardial injury and has a bright future. It is much more difficult to predict the future for today's discoveries! The identification of myocardial injury has become much more complicated than the identification of ST segment elevation on the surface ECG. In large part, this complexity is the result of the extreme sensitivity of the current biomarkers of myocardial injury. It is amazing, to me at least, what is considered a myocardial injury biomarker. For this commentary, I'm going to ignore topical biomarkers that do not originate from the heart (e.g. ST2, Galectin3, GDF15, copeptin and adrenomedullin) since their biology dictates they become elevated in conditions other than acute myocardial injury (i.e. prone to false positives that limit specificity). I'm also going to ignore imaging biomarkers (e.g. late gadolinium enhancement and oedema imaging on MRI) since they are not capable of measuring small volumes of myocardial injury (prone to false negatives that limit sensitivity). So the focus is on biomarkers originating from the heart that have extreme sensitivity and specificity.
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The biomarker that best indicates myocardial injury is without doubt cardiac troponin (cTn). It has revolutionised the identification of acute myocardial infarction (AMI), which by definition now cannot be diagnosed unless the cTn concentration in the blood rises above the 99th centile found in the healthy population. 1 However, recently cTns have become the victim of their own success. cTn is released relatively slowly into the systemic circulation after myocardial injury and does not reach its peak concentrations until about 36 h after the event. In an attempt to diagnose early injury, well before this peak, the assay vendors have created exquisite analytic masterpieces that can reliably measure, in the protein soup that is blood, cTn concentrations in the low femtomolar range (1-2 ng/L). The result is that the latest assays can measure cTn in the peripheral blood in more than 50% of healthy people. However, even in apparently healthy ambulatory patients concentrations increase with age, renal impairment and other cardiovascular risk factors. As a consequence 20-40% of patients attending A þ E without a final diagnosis of AMI have a cTn concentration above the 99th centile. This has caused intense frustration since cTn can no longer be used as a binary test and clinicians think the new high sensitivity cTn assays give rise to too many false positives. The real issue is that the best assays provide a precise measurement of the whole spectrum of cTn concentrations and there is not a single cut-off that will differentiate acute injury from chronic injury. Even in those with acute injury, the assays cannot differentiate an atherosclerotic plaque rupture event (type 1 AMI) from other forms of myocyte necrosis. The question is how in the future can these deficiencies be overcome?
Mike Marber is a physician scientist with basic research interests in the processes causing heart cell death and clinical interests in patient care during and after acute myocardial infarction. Surprising, to me at least, is the disconnect between the cardiac physiologists/biophysicists that study the role of cTn in the sarcomere and the scientists that develop the diagnostic assays. All the current highsensitivity assays employ capture and detection antibodies to epitopes that lie in close promity. This is to ensure that a cleavage event (between capture and detection sites) does not destroy analytic sensitivity. However, the design is agnostic to the exquisite and extensive post translational modifications that regulate cTns and cTnI in particular. These events may also determine the repertoire of circulating fragments. 2 Thus there is much more information available than 'mere' cTn concentration, and the obsession with measuring extremely low concentrations that drives current commercial development. Thus, my prediction is that cTn assays are here to stay but in the future they will evolve to more exquisitely track the biology responsible for release from the heart. In this way, they may be able to differentiate between different forms of myocardial injury and most importantly, differentiate chronic injury from AMI. The slow release of cTn is a major drawback limiting the early diagnosis of AMI. cTn also persists in the circulation for days, limiting its use for diagnosis of re-infarction. These drawbacks led us to search for cardiacrestricted proteins that are released easily during myocardial ischaemia. We found cardiac myosin-binding protein C (cMyBP-C or cMyC TM ) 3 and developed a sensitive immunoassay. 4 We compared the release and clearance profiles of cMyC to cTnT using a model of iatrogenic myocardial infarction (therapeutic alcohol ablation of septal obstruction in hypertrophic cardiomyopathy) and brisk myocardial reperfusion (after cardiopulmonary bypass reduction), respectively. 5 These studies showed cMyC appears and disappears from the circulation more quickly than cTnT. We also showed, that like cTnT and cTnI, the cMyC assay is exquisitely sensitive and capable detecting microscopic amounts of myocardial necrosis, way below the limit that can be identified with current imaging techniques. 6 Ultimately, these characteristics enabled cMyC to triage patients attending the Emergency Department with suspected AMI, at least as well as the leading troponin assays. 7 Like cTnI, cMyC is also subject to posttranslational modifications that indicate cardiac function and may from a poison peptide that depresses contractility. Furthermore, cMyC can definitely also be used as a marker of chronic myocardial injury. 8 In summary, to paraphrase US electioneering slogans; 'It's the biology, stupid'. The future of myocardial injury biomarkers lies in those that actually originate from the heart, we just need to listen more carefully!
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